Key Takeaways Ocugen's stock outlook hinges on late-stage data and filings across three retinal programs.OCGN reported $67.8M net loss in 2025, with rising R&D and pre-commercial costsCash runway into late 2026 raises dilution risk ahead of potential approvals in 2027Ocugen (OCGN) is entering a period where the stock can be driven more by calendar-based catalysts than traditional fundamentals. Multiple late-stage readouts and filing steps are lined up across its three lead retinal programs through 2026 and ...